Zebra Ventures

06/05/2016

We've been there! As authors and as readers.

25/04/2016

Me and 40 million Americans with a condition called steatoblepharon. Looking forward seeing this drug come to the market! http://www.fiercebiotech.com/biotech/allergan%E2%80%99s-new-85m-buyout-adds-a-cosmetic-drug-to-a-growing-portfolio

The buyout gives Allergan a late-stage drug dubbed XA5F, which is designed to smooth and erase bulging bags under the eye.

24/04/2016

"On Resilience Genes as Drug Targets and Implications for Cistic Fibrosis" by on https://www.linkedin.com/pulse/resilience-genes-drug-targets-implications-cistic-fibrosis-zecevic

During the Basic Science ECFS meeting last month, much was said about individual differences among CFTR mutation carrying individuals and how same genotypes can give rise to a very different

28/10/2015

This is what we expect of our clients: be able to use "track changes" and "reply to all", not use font above 14, be younger than 75.
Learned the hard way!

28/09/2015

September cystic fibrosis newsletter is out: check out our Tech Transfer lesson of the month! http://eepurl.com/bAGJO9

The criteria for making and presenting an interesting poster at a scientific event are different from the standards required to get a manuscript published in a peer review journal. This can sometimes be an advantage that allows the scientist to present novel data and initiate a dialogue with potenti…

15/09/2015

Check out our new blog post on hot buzz words - , , , http://goo.gl/69BnDh

Zebra Ventures Srl Via Errico Petrella 22 20124 Milano www.twozebras.com phone: +39 02 871 68 737 [email protected] P.IVA IT06550300963

26/06/2015

New on CF Industry Liaison Office site: Integrated approach to pick up CFTR correctors like: discovery opportunity in from University of Genova
http://media.wix.com/ugd/348b3d_d7b6e52522e44dbea4713613d1141a5b.pdf

24/06/2015

new cystic fibrosis newsletter is out, focus on industry perspective in this issue http://eepurl.com/brj7KL

Biopharmaceutical companies are always looking for drug candidates that are complementary with their existing corporate strategy. When evaluating external opportunities in early stages of research and development, companies are typically looking for the following features: